Ultrabright NIR AIEgen nanoparticles‐enhanced lateral flow immunoassay platform for accurate diagnostics of complex samples
Jia Shu,Yujian Li,Huan Cai,Qing Fu,Chunyang Li,Jianbo Yuan,Yan Zhao,Changjin Liu,Haiping Wu,Doudou Ling,Zhangluxi Liu,Guannan Su,Qingfeng Cao,Xiaolin Huang,Rui Chen,Peizeng Yang
DOI: https://doi.org/10.1002/agt2.551
2024-04-11
Aggregate
Abstract:Ultrabright near‐infrared (NIR) AIEgen nanoparticles (PS@AIE830NPs) with an ultrahigh relative quantum yield of 14.76% were designed and proposed as an improved signal label to achieve accurate and sensitive point‐of‐care testing. In combination with luminescent lateral flow immunoassay (LFIA), PS@AIE830NPs can effectively eliminate background interference and enable direct detection of target analytes in complex samples without any pre‐treatment steps. This work demonstrated an accurate NIR LFIA platform using PS@AIE830NPs to enhance diagnostic accuracy and sensitivity. Accurate and sensitive near‐infrared (NIR) luminescent lateral flow immunoassay (LFIA) has attracted considerable attention in the field of point‐of‐care testing (POCT). However, the detection accuracy and sensitivity are often compromised by the low fluorescence quantum efficiency ( 800 nm) completely eliminated background interference and allowed highly accurate and sensitive detection without any pre‐treatment steps. The limits of detection (LODs) for aflatoxin B1 (AFB1) in soy sauce, alpha hemolysin (Hla) of Staphylococcus aureus biomarker in joint fluid, and C‐reactive protein (CRP) in human haemolysed samples were 0.01 ng mL−1, 0.02 μg mL−1, and 0.156 mg L−1, respectively, commensurating with those of the corresponding gold standard assays and covering the detection range of interests. It is anticipated that the ultrabright NIR AIEgen nanoparticles will serve as a universally applicable signal probe for NIR‐LFIA diagnostics, promising to expand the range of applications for quantitative detection of complex samples.
chemistry, multidisciplinary, physical,materials science